Human Recombinant Tissue-Plasminogen Activator (Alteplase): Why Not Use the ‘Human’ Dose for Stroke Studies in Rats? | Zendy

Benoît Haelewyn | Zendy; JeanJacques Risso | Zendy; Jacques H. Abraini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Human Recombinant Tissue-Plasminogen Activator (Alteplase): Why Not Use the ‘Human’ Dose for Stroke Studies in Rats?

Author(s) -

Benoît Haelewyn,

JeanJacques Risso,

Jacques H. Abraini

Publication year - 2010

Publication title -

journal of cerebral blood flow and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.167

H-Index - 193

eISSN - 1559-7016

pISSN - 0271-678X

DOI - 10.1038/jcbfm.2010.33

Subject(s) - recombinant tissue plasminogen activator , tissue plasminogen activator , medicine , stroke (engine) , t plasminogen activator , pharmacology , thrombolysis , plasminogen activator , fibrinolytic agent , recombinant dna , anesthesia , ischemia , ischemic stroke , chemistry , myocardial infarction , biochemistry , mechanical engineering , modified rankin scale , engineering , gene

Since a pioneer work that has shown in vitro that the rat's fibrinolytic system is 10-fold less sensitive to recombinant tissue-plasminogen activator (rtPA) than the human system, most preclinical studies are performed with 10 instead of 0.9 mg/kg rtPA (the clinical dose in stroke patients). In this study, we compared the effects of these doses on mean time to reperfusion, reperfusion slope, brain infarct volume and edema in a rat model of thrombo-embolic stroke. Our data provide evidence that the dose of 0.9 mg/kg rtPA is as appropriate as that of 10 mg/kg for preclinical stroke studies in rodents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research